VANCOUVER, BC, Nov. 24, 2020 /CNW/ - InMed Pharmaceuticals
Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a
clinical-stage pharmaceutical company developing medications
targeting diseases with high unmet medical need and leading the way
in the clinical development of cannabinol ("CBN"), today confirmed
that, at its annual general and special meeting of shareholders
held on November 20, 2020 (the
"Meeting"), all of the matters put forward before shareholders for
consideration and approval as set out in InMed's notice of meeting
and management information circular, dated October 7, 2020, were approved by the
shareholders. In particular, shareholders approved the election of
all director nominees to hold office until the next annual meeting
of shareholders or until their successors are elected or appointed.
Results of the vote for the election of directors at the Meeting
are set out as follows:
Director
|
Votes
For
|
|
Withheld
Votes
|
Number
|
Percentage
|
|
Number
|
Percentage
|
Eric A.
Adams
|
639,176
|
90.84%
|
|
64,464
|
9.16%
|
Adam
Cutler
|
654,431
|
93.01%
|
|
49,209
|
6.99%
|
William J.
Garner
|
644,945
|
91.66%
|
|
58,695
|
8.34%
|
Andrew
Hull
|
654,149
|
92.97%
|
|
49,491
|
7.03%
|
Catherine
Sazdanoff
|
653,532
|
92.88%
|
|
50,108
|
7.12%
|
InMed filed a report of voting results on SEDAR at www.sedar.com
on November 24, 2020.
About InMed: InMed Pharmaceuticals is a clinical-stage
pharmaceutical company developing a pipeline of cannabinoid-based
medications, initially focused on the therapeutic benefits of
cannabinol (CBN) in diseases with high unmet medical need. The
Company is dedicated to delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines. For
more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: leading the way in the clinical development of
CBN; developing a pipeline of cannabinoid-based medications in
diseases with high unmet medical need; and delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based medicines.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
View original
content:http://www.prnewswire.com/news-releases/inmed-announces-election-of-directors-301180215.html
SOURCE InMed Pharmaceuticals Inc.